Journal Options Hepatitis
Course Directors: Raymond T. Chung, MD, Robert G. Gish, MD, Stephen A. Harrison, MD, LTC, MC
Featured Expert Commentary
Tarek Hassanein, MD
Professor of Clinical Medicine and Surgery
Division of Gastroenterology and Hepatology
University of California, San Diego
Director of Liver Transplantation
UCSD Liver Center
University of California, San Diego
San Diego, California
Recent Articles
Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alfa-2b.
Buster EH, Flink HJ, Cakaloglu Y, et al. Gastroenterology. 2008;135:459-467. Capsule Summary | Expert Commentary | Abstract | Slides
Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.
Ferenci P, Laferl H, Scherzer TM, et al. Gastroenterology. 2008;135:451-458. Capsule Summary | Expert Commentary | Abstract | Slides
Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alfa-2a and ribavirin.
Fried MW, Jensen DM, Rodriguez-Torres M, et al. Hepatology. 2008;48:1033-1043. Capsule Summary | Expert Commentary | Abstract | Slides
Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
Korba BE, Elazar M, Lui P, Rossignol JF, Glenn JS. Antimicrob Agents Chemother. 2008;52:4069-4071. Capsule Summary | Expert Commentary | Abstract | Slides
Sorafenib in advanced hepatocellular carcinoma.
Llovet JM, Ricci S, Mazzaferro V, et al. N Engl J Med. 2008;359:378-390. Capsule Summary | Expert Commentary | Abstract | Slides
Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C.
Loustaud-Ratti V, Alain S, Rousseau A, et al. Hepatology. 2008;47:1453-1461. Capsule Summary | Expert Commentary | Abstract | Slides
Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial.
Mangia A, Minerva N, Bacca D, et al. Hepatology. 2008;47:43-50. Capsule Summary | Expert Commentary | Abstract | Slides
Rapid virologic response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.
Yu ML, Dai CY, Huang JF, et al. Hepatology. 2008;47:1884-1893. Capsule Summary | Abstract | Slides
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.
Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. Ann Intern Med. 2006;144:705-714. Abstract
A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients.
Bain VG, Kaita KD, Yoshida EM, et al. J Hepatol. 2006;44:671-678. Abstract
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
Nov/Dec 2005
Collection
Hepatitis JournalOptions – November/December 2005
CME Program Director: Robert G. Gish, MD, David L. Thomas, MD, MPH
  
- Nezam H. Afdhal, MD, FRCPI
- Rena K. Fox, MD
- Neil Kaplowitz, MD
|
  
- Paul J. Pockros, MD
- Stuart Ray, MD
- Kathleen B. Schwarz, MD
|
Sept/Oct 2005
Collection
Hepatitis JournalOptions – September/October 2005
CME Program Director: Robert G. Gish, MD, David L. Thomas, MD, MPH
  
- Hal B. Jenson, MD, MBA
- Emmet B. Keeffe, MD, MACP
- Daryl T-Y Lau, MD, MSc, MPH, FRCP(C)
|
 
- Paul Martin, MD
- Philip Rosenthal, MD
- Richard K. Sterling, MD
|
|